Home / Peptide legality / Minnesota
Are peptides legal in Minnesota?
Peptides sit in a gray zone in Minnesota: FDA-approved peptide drugs are legal with a prescription and patient-specific compounding is allowed through a licensed pharmacy, but the Minnesota Board of Pharmacy enforces strict USP 797 sterile rules, bars unapproved salt forms, and treats research-use-only peptides as unlawful.
Legal status overview
Peptides sit in a gray zone in Minnesota. FDA-approved peptide medicines such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal when prescribed after a valid patient evaluation, and a licensed 503A or 503B pharmacy may prepare compounds, though those compounds are not FDA-approved, not a generic, and not evaluated by the FDA. The Minnesota Board of Pharmacy requires strict USP Chapter 797 compliance for injectable peptides and explicitly prohibits unapproved salt forms such as semaglutide sodium and semaglutide acetate. Peptides labeled research-use-only are unapproved drugs whose use for humans violates state and federal law, and BPC-157 remains outside the eligible compounding lists.
Key points
- FDA-approved peptide drugs such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal in Minnesota when prescribed after a legitimate patient evaluation. [4]
- Under Minnesota Rule 6800.3300, any pharmacy compounding sterile products, including injectable peptides and GLP-1 medications, must follow USP Chapter 797 standards. [4]
- The Minnesota Board of Pharmacy explicitly prohibits unapproved salt forms such as semaglutide sodium and semaglutide acetate and treats them as adulterated drugs. [5]
- Compounded semaglutide is permitted only when a licensed provider documents a patient-specific clinical reason and it is prepared by a licensed 503A or 503B pharmacy, and those compounds are not FDA-approved, not a generic, and not evaluated by the FDA. [4]
- Large-scale, essentially-a-copy GLP-1 compounding ended after the FDA declared the shortages resolved, with tirzepatide off the shortage list in October 2024 and semaglutide in February 2025. [3]
- Using peptides labeled research-use-only is an explicit violation of state and federal law in Minnesota and can trigger loss of a professional license. [5]
- BPC-157 was removed from the FDA Category 2 bulk-substances list in April 2026 but was not added to Category 1, so it is not an eligible bulk substance for Section 503A compounding. [7]
- Minnesota law allows a prescriber-patient relationship to be established via telehealth for non-controlled prescriptions, but the prescriber must evaluate history, examination, and relevant labs before prescribing a GLP-1. [5]
Compound-by-compound status
| BPC-157 Restricted | Unapproved new drug. Removed from FDA Category 2 in April 2026 but not placed in Category 1, so it is not eligible for Section 503A compounding. Not FDA-approved, not a generic, and not evaluated by the FDA. |
|---|---|
| GLP-1 class (semaglutide, tirzepatide) Legal | Branded FDA-approved products such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal with a prescription. Compounded GLP-1 preparations are limited to documented patient-specific need, must use an approved active ingredient rather than a prohibited salt form, and are not FDA-approved, not a generic, and not evaluated by the FDA. |
| TB-500 (thymosin beta-4) Illegal | Unapproved new drug with no FDA-approved human indication. Selling or using it for human consumption, including as a research chemical, violates state and federal law. |
| Growth hormone / somatropin Legal | A prescription drug legal only for FDA-approved indications under a valid prescription and dispensed by a licensed pharmacy. Federal law separately restricts human growth hormone distribution outside approved uses. |
Frequently asked questions
Are peptides legal in Minnesota?
FDA-approved peptide drugs are legal with a prescription, and licensed pharmacies may compound patient-specific preparations under strict USP 797 rules. Research-use-only peptides are unlawful for human use. This is information, not medical advice.
Can Minnesota pharmacies compound semaglutide?
Yes, but only for a documented patient-specific clinical need through a licensed 503A or 503B pharmacy, using an approved active ingredient and not a prohibited salt form. Compounded semaglutide is not FDA-approved, not a generic, and not evaluated by the FDA.
Why does Minnesota ban semaglutide sodium and semaglutide acetate?
The Minnesota Board of Pharmacy treats those unapproved salt forms as adulterated drugs, so compounders must use an approved active pharmaceutical ingredient instead.
Is BPC-157 legal in Minnesota?
BPC-157 is an unapproved drug and is not on the FDA list of substances eligible for compounding, so it is not cleared for clinical use despite its April 2026 removal from Category 2.
Can I start a GLP-1 prescription by telehealth in Minnesota?
Minnesota permits establishing the prescriber-patient relationship via telehealth for non-controlled prescriptions, provided the clinician evaluates history, performs an appropriate examination, and reviews relevant labs first.
Sources
- Minnesota Board of Pharmacy: 2025 Legislation (retrieved 2026-09-21)
- FDA: Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (retrieved 2026-09-21)
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize (retrieved 2026-09-21)
- Holt Law: Federal and State Regulatory Framework for Compounded Injectable Drugs and Peptides in Minnesota (retrieved 2026-09-21)
- Holt Law: The Future of GLP-1 Enforcement in Minnesota (retrieved 2026-09-21)
- Sheppard Mullin: Above the Federal Floor, How States Are Regulating Compounded GLP-1s and Peptides (retrieved 2026-09-21)
- Holt Law: BPC-157 in 2026, Why Regulatory Limbo Is Not the Same as a Green Light (retrieved 2026-09-21)
Last researched: 2026-09-21.